Figure 2From: Improvement of quality of life in patients with concomitant allergic asthma and atopic dermatitis: one year follow-up of omalizumab therapy Time course of DLQI that was significantly in favor of omalizumab treatment in the atopic dermatitis/asthma group (P < 0.05: 2 months, 3 months, 6 months and 12 months vs. baseline).Back to article page